Adam V. Patterson - Concepedia

Author

Adam V. Patterson

Also Known As

A PATTERSON, A Patterson, A V Patterson, A. Patterson, A. V Patterson, A. V. Patterson, A.V Patterson, A.V. Patterson, ADAM V. PATTERSON, AV Patterson

262

Publications

6.7K

Citations

H-Index

Concepts

All Affiliations

University of Auckland Cancer Society of New Zealand Maurice Wilkins Centre Victoria University of Wellington University of Manchester

About

Adam V. Patterson is an author at University of Auckland specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	54	3.4K
2	Biochemistry	23	29	1.7K
3	Natural Sciences	14	14	678
4	Engineering	2	2	152
5	Health Sciences	2	2	150

Adam V. Patterson

Publications

5.1K

Citations

H-Index

Page 1

	Year	Citations
Targeting gene expression to hypoxic tumor cells Gabi U. Dachs, Adam V. Patterson, John D. Firth, Nature Medicine Tumor BiologyRedox RegulatorMedicineTumor SuppressorGene Expression	1997	367
Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Rachel Airley, J. Loncaster, S.E. Davidson, PubMed PathologyMetastasis-free SurvivalCancer BiologyTumor BiologyOxidative Stress	2001	326
Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104 Adam V. Patterson, Dianne M. Ferry, Shelley J. Edmunds, Clinical Cancer Research	2007	243
Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302 Fanying Meng, James Evans, Deepthi Bhupathi, Molecular Cancer Therapeutics PharmacotherapyRedox BiologyOxidative StressMolecular PharmacologyRedox Regulator	2011	203
The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3 Christopher P. Guise, Maria R. Abbattista, Rachelle S. Singleton, Cancer Research Cancer MetabolismReductive StressTumor HypoxiaPr-104 Antitumor ActivityAldo-keto Reductase	2010	185
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed Y. Yosaatmadja, Shevan Silva, James M. Dickson, Journal of Structural Biology Signal TransductionSignaling PathwayG Protein-coupled ReceptorBreakthrough Inhibitor Azd9291Growth Factor Receptor	2015	145
Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954 G.A. Prosser, JN Copp, S. P. Syddall, Biochemical Pharmacology BiochemistryReactive Nitrogen SpecieAnti-cancer Prodrug Cb1954Escherichia Coli NitroreductasesMicrobiology	2009	128
TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure Maria Kalyukina, Y. Yosaatmadja, Martin Middleditch, ChemMedChem	2019	118
Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials Linda Spiegelberg, Ruud Houben, Raymon Niemans, Clinical and Translational Radiation Oncology Clinical ProgressPharmacotherapyTumor BiologyOxidative StressTranslational Medicine	2019	114
Structure−Activity Relationships of 1,2,4-Benzotriazine 1,4-Dioxides as Hypoxia-Selective Analogues of Tirapazamine Michael P. Hay, Swarna A. Gamage, Mary S. Kovacs, Journal of Medicinal Chemistry Pharmaceutical ScienceHypoxia-selective AnaloguesPharmacotherapyChemistryHeterocycle Chemistry	2002	111

Page 1